初次诱导治疗七至十天骨髓白血病细胞下降指数与急性髓系白血病预后的关系

Prognostic significance of the marrow blast decline index in AML （not APL） at the first inductive treatment for 7-10 days

目的观察初发急性髓系白血病（AML）[非急性早幼粒细胞白血病（APL）]诱导治疗7-10d骨髓白血病细胞下降指数（MBDI）与预后的关系。方法回顾性分析109例AML（非APL）患者，比较持续缓解组、复发组、未缓解组初次诱导治疗7～10dMBDI的差异；进行该指数与持续缓解率、复发率的相关分析。结果MBDI均值持续缓解组为0．8856，显著高于复发组（0．4445）和未缓解组（0．3903）（P〈0．0001）；该指数与持续缓解率呈正相关（P〈0．01），与复发率呈负相关（P〈0．01）。结论初次诱导治疗7—10d时MBDI对AML（非APL）具有早期判断预后的价值。

Objective To investigate relationship of the marrow blast decline index （MBDI） in AML （not APL） at the first inductive treatment for 7-10 days and the prognosis. Methods 109 cases of AML were retrospectively analyzed （not APL）, to compare the marrow blast decline index in AML（not APL） at the first inductive treatment for 7-10 days in the continue relieve group, the relapse group and the non-remission group, analyzed the correlation of the MBDI and continue relapse rate, the MBDI and relapse rate. Results The MBDI mean value is 0.8856 in continue relieve group, significantly higher than that of the relapse group （mean =0.4445） and the non-remission group（mean =0.3903） （P 〈0.0001）. The MBDI positively correlated with continue relapse rate （P 〈0.01）; negatively correlated with relapse rate （P 〈0.01）. Conclusion The marrow blast decline index in AML（not APL） at the first inductive treatment for 7-10 days was significant for early assesment of the prognosis.